Related Experiment Videos
Selection and management of patients for cardiac transplantation
1Ahmanson-UCLA Cardiomyopathy Center, Los Angeles, CA.
Insights
Advanced heart failure patients may avoid or delay cardiac transplantation with optimized medical therapy. Improved risk identification and management can enhance quality of life and survival for these candidates.
Area of Science:
- Cardiology
- Transplantation Medicine
- Advanced Heart Failure Management
Background:
- Approximately 170 cardiac transplantations and 300 new listings occur monthly in the US.
- Managing advanced heart failure patients awaiting transplantation presents unique prognostic and therapeutic challenges.
- Standard heart failure trial results may not apply to advanced stages of the disease.
Purpose of the Study:
- To investigate strategies for managing advanced heart failure patients.
- To identify patients suitable for alternative therapies or transplantation.
- To improve outcomes for candidates awaiting cardiac transplantation.
Main Methods:
- Review of prognostic factors and therapeutic principles in advanced heart failure.
- Analysis of quality of life and survival in patients with low ejection fractions and severe symptoms.
- Evaluation of medical therapy optimization and risk factor identification.
Main Results:
- Many advanced heart failure patients with low ejection fractions can achieve transplant-equivalent quality of life and survival.
- Optimized medical therapy and risk stratification are crucial for patient management.
- Effective management can help patients defer or avoid transplantation.
Conclusions:
- Improvements in medical therapy design and risk factor identification are key.
- These advancements can enable patients to avoid or delay transplantation.
- Stable management until transplantation is achievable for the majority of candidates.
Abstract:
Each month in the United States, approximately 170 patients undergo cardiac transplantation and 300 new candidates are listed. Provision of alternative therapies, identification of the patients who truly have no other option, and management of those candidates until transplantation is performed has created a challenging area of investigation. The results of heart failure trials conducted in populations with milder heart failure may not always extend to advanced heart failure, to which some prognostic and therapeutic principles are unique. Many patients with low ejection fractions and a history of severe heart-failure symptoms can nonetheless enjoy quality of life and survival equivalent to those of patients who have received transplants. Improvements in our ability to design optimal medical therapy and to identify risk factors for early mortality will allow many patients with advanced heart failure to defer or avoid transplantation, and enable the majority of candidates to remain stable until transplantation can be performed.